You are here

Duchenne Muscular Dystrophy

Catabasis Plans Ph III Trial for Edasalonexent in Duchenne Muscular Dystrophy

Catabasis Plans Ph III Trial for Edasalonexent in Duchenne Muscular Dystrophy

CP Wire

clinical trials

Duchenne Muscular Dystrophy

Flag link:

Catabasis Plans Ph III Trial for Edasalonexent in Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Flag link:

Summit Therapeutics Ditches Duchenne Drug In Wake of Phase 2 Failure

Summit Therapeutics Ditches Duchenne Drug In Wake of Phase 2 Failure

Xconomy

Summit Therapeutics

clinical trials

Duchenne Muscular Dystrophy

Flag link:

[video/transcript]Sarepta Therapeutics Could Be Onto Something Big

[video/transcript]Sarepta Therapeutics Could Be Onto Something Big

Motley Fool

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Early access to Santhera’s DMD therapy Raxone extended in the UK

Early access to Santhera’s DMD therapy Raxone extended in the UK

Pharma Times

Duchenne Muscular Dystrophy

Flag link:

3 patients add $2.5B to Sarepta's value

3 patients add $2.5B to Sarepta's value

Biopharma Dive

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

With tantalizing early results, Sarepta’s gene therapy for Duchenne raises hopes for ‘real change’

With tantalizing early results, Sarepta’s gene therapy for Duchenne raises hopes for ‘real change’

Stat

Sarepta Therapeutics

Duchenne Muscular Dystrophy

clinical trials

Flag link:

As Sarepta Preps Data, FDA Lifts Hold on Solid’s Duchenne Gene Therapy

As Sarepta Preps Data, FDA Lifts Hold on Solid’s Duchenne Gene Therapy

Xconomy

Duchenne Muscular Dystrophy

Solid Biosciences

Sarepta Therapeutics

Flag link:

Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug

Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug

Endpoints

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Catabasis Pharmaceuticals' Edasalonexent Slowed Duchenne Muscular Dystrophy Disease Progression Through One Year of Treatment

Catabasis Pharmaceuticals' Edasalonexent Slowed Duchenne Muscular Dystrophy Disease Progression Through One Year of Treatment

CP Wire

Duchenne Muscular Dystrophy

Flag link:

Catabasis Pharmaceuticals' Edasalonexent Slowed Duchenne Muscular Dystrophy Disease Progression Through One Year of Treatment

Duchenne Muscular Dystrophy

Flag link:

Daiichi Sankyo concedes an early setback on Duchenne MD drug, but doubles down on development

Daiichi Sankyo concedes an early setback on Duchenne MD drug, but doubles down on development

Endpoints

Duchenne Muscular Dystrophy

Flag link:

Solid Biosciences Provides Update on Clinical Hold of Ph I/II Trial for Duchenne Muscular Dystrophy (DMD)

Solid Biosciences Provides Update on Clinical Hold of Ph I/II Trial for Duchenne Muscular Dystrophy (DMD)

CP Wire

Solid Biosciences

Duchenne Muscular Dystrophy

clinical trials

Flag link:

Catabasis Pharmaceuticals Reduces Workforce by 42% to Focus on Developing Edasalonexent for Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals Reduces Workforce by 42% to Focus on Developing Edasalonexent for Duchenne Muscular Dystrophy

CP Wire

Duchenne Muscular Dystrophy

Flag link:

Solid Biosciences Provides Update on Clinical Hold of Ph I/II Trial for Duchenne Muscular Dystrophy (DMD)

Solid Biosciences

Duchenne Muscular Dystrophy

Flag link:

Catabasis Pharmaceuticals Reduces Workforce by 42% to Focus on Developing Edasalonexent for Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Flag link:

Pfizer Commences Ph Ib Trial With Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

Pfizer Commences Ph Ib Trial With Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

CP Wire

Duchenne Muscular Dystrophy

Flag link:

Should Sarepta’s patents be seized by the government? Patient advocates pitch controversial drug pricing proposal

Should Sarepta’s patents be seized by the government? Patient advocates pitch controversial drug pricing proposal

Endpoints

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Solid Bio's DMD gene therapy graduates from partial FDA hold to full-on clinical hold

Solid Bio's DMD gene therapy graduates from partial FDA hold to full-on clinical hold

Fierce Biotech

Solid Biosciences

Duchenne Muscular Dystrophy

Flag link:

Sarepta to seek FDA approval for its second Duchenne’s drug by year’s end

Sarepta to seek FDA approval for its second Duchenne’s drug by year’s end

Stat

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Flag link:

Pages